Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $18.47 USD
Change Today +0.007 / 0.04%
Volume 19.1K
LMNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:12 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMNX) Snapshot

Open
$18.35
Previous Close
$18.46
Day High
$18.58
Day Low
$18.35
52 Week High
10/10/14 - $21.69
52 Week Low
02/3/15 - $15.05
Market Cap
798.5M
Average Volume 10 Days
252.3K
EPS TTM
$1.12
Shares Outstanding
43.0M
EX-Date
--
P/E TM
16.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for LUMINEX CORP (LMNX)

Related News

No related news articles were found.

luminex corp (LMNX) Related Businessweek News

No Related Businessweek News Found

luminex corp (LMNX) Details

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics and life sciences industries worldwide. It offers xMAP technology, an open architecture, multiplexing technology that allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The company’s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; respiratory viral family of products, including respiratory viral panel to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel family of products, such as in vitro diagnostic (IVD) assays to identify the pathogens causing infectious gastroenteritis. In addition, the company offers MultiCode assays and products comprising HSV1/2 kits, analyte specific reagents, and other products to detect infectious agents in clinical samples; cystic fibrosis family of products comprising IVD kits for cystic fibrosis genotyping; personalized medicine family of products consisting of assays to determine the drug metabolism status; and specialty product family and instrumentation products, as well as operates an original equipment manufacturer of custom reagents and instrumentation. It serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.

745 Employees
Last Reported Date: 02/25/15
Founded in 1995

luminex corp (LMNX) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $275.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $370.8K
Senior Vice President - Research & Developmen...
Total Annual Compensation: $327.0K
Chief Marketing & Sales Officer and Senior Vi...
Total Annual Compensation: $334.3K
Compensation as of Fiscal Year 2014.

luminex corp (LMNX) Key Developments

Luminex Corporation Submits 510(K) Application for the NxTAG® Respiratory Pathogen Panel

Luminex Corporation announced that it has submitted a 510(k) application to the FDA for the company's NxTAG® Respiratory Pathogen Panel. This panel is the only respiratory assay that will easily enable laboratories to simultaneously detect 21 respiratory pathogens in a single closed tube system in a format that scales to changes in throughput requirements and responds to seasonal changes in demand. The NxTAG Respiratory Pathogen Panel requires only minutes of hands-on time with no upstream reagent preparation. Extracted samples are added directly to pre-plated, lyophilized reagents. The tubes are then sealed and ready for closed tube amplification and subsequent detection using the Luminex MAGPIX® instrument. The innovative tube strip design offers laboratories the flexibility to manage variable sample demand by processing a single sample or up to as many as 96 samples per run, without wasting consumables or reagents, and the total turnaround time is only about three hours for 96 samples (excluding extraction). In addition, the accompanying SYNCT™ Software provides a comprehensive approach to data analysis and reporting, and enables the NxTAG Respiratory Pathogen Panel to integrate easily into any laboratory.

Luminex Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Third Quarter of 2015; Revises Earnings Guidance for the Full Year 2015

Luminex Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenue was $58.917 million against $55.632 million a year ago. Income from operations was $9.959 million against $4.771 million a year ago. Income before income taxes was $2.916 million against $4.770 million a year ago. Net income was $2.629 million or $0.06 per basic and diluted share against $4.725 million or $0.11 per basic and diluted share a year ago. Net cash provided by operating activities was $20.557 million against $10.227 million a year ago. Purchase of property and equipment was $3.670 million against $3.150 million a year ago. Acquired technology rights was $0.025 million against $0.064 million a year ago. Adjusted income from operations was $14.165 million against $9.857 million a year ago. Adjusted net income was $11.592 million or $0.27 per diluted share against $8.497 million or $0.20 per diluted share a year ago. For the six months, revenue was $116.658 million against $112.193 million a year ago. Income from operations was $19.652 million against $12.956 million a year ago. Income before income taxes was $13.303 million against $12.930 million a year ago. Net income was $10.082 million or $0.24 per basic and diluted share against $10.691 million or $0.26 per basic and diluted share a year ago. Net cash provided by operating activities was $31.492 million against $21.664 million a year ago. Purchase of property and equipment was $12.568 million against $6.255 million a year ago. Acquired technology rights was $0.202 million against $0.064 million a year ago. Adjusted income from operations was $26.813 million against $22.336 million a year ago. Adjusted net income was $21.178 million or $0.50 per diluted share against $18.369 million or $0.44 per diluted share a year ago. For the third quarter of 2015, the company anticipates revenue to be between $56 million and $58 million. For the full year of 2015, the company currently expects full year effective tax rate to be approximately 25% as is reflected in ETR for the year-to-date period. Considering first half performance, the company is raising the lower end of 2015 revenue guidance by $2 million to $232 million, resulting in a revised revenue guidance range between $232 million and $236 million. New 2015 revenue guidance range balances continued execution with respect to molecular diagnostic assay portfolio, which the company expects to grow in the mid- to low teens in 2015, offset somewhat from the timing of consumable reorders from large partner.

Luminex Corporation Submits FDA 510(k) Submissions for ARIES™ System and ARIES™ HSV 1&2 Assay

Luminex Corporation announced that it has submitted 510(k) applications to the FDA for the company's ARIES™ System and ARIES™ HSV 1&2 Assay. The company anticipates receiving FDA clearance and CE-IVD marking before the end of 2015. Clinical trials for the ARIES C. difficile Assay and the ARIES Group B Streptococcus (GBS) Assay are progressing, and the company expects to launch clinical trials for additional ARIES products prior to the end of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNX:US $18.47 USD +0.007

LMNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $9.32 USD -0.16
HealthStream Inc $25.46 USD +0.10
Merge Healthcare Inc $7.09 USD 0.00
Meridian Bioscience Inc $19.18 USD +0.065
Quidel Corp $20.50 USD +0.05
View Industry Companies
 

Industry Analysis

LMNX

Industry Average

Valuation LMNX Industry Range
Price/Earnings 20.3x
Price/Sales 3.4x
Price/Book 2.3x
Price/Cash Flow 18.9x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit www.luminexcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.